WLM Medical Solutions Ltd 10784771 false 2023-06-01 2024-08-31 2024-08-31 The principal activity of the company is that of pharmaceutical industry connected to an Italian company These are final trading accounts and the company will soon be dissolved. Digita Accounts Production Advanced 6.30.9574.0 true 10784771 2023-06-01 2024-08-31 10784771 2024-08-31 10784771 core:RetainedEarningsAccumulatedLosses 2024-08-31 10784771 core:ShareCapital 2024-08-31 10784771 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-31 10784771 bus:SmallEntities 2023-06-01 2024-08-31 10784771 bus:AuditExemptWithAccountantsReport 2023-06-01 2024-08-31 10784771 bus:AbridgedAccounts 2023-06-01 2024-08-31 10784771 bus:SmallCompaniesRegimeForAccounts 2023-06-01 2024-08-31 10784771 bus:RegisteredOffice 2023-06-01 2024-08-31 10784771 bus:Director2 2023-06-01 2024-08-31 10784771 bus:PrivateLimitedCompanyLtd 2023-06-01 2024-08-31 10784771 core:RetainedEarningsAccumulatedLosses 2023-06-01 2024-08-31 10784771 core:ShareCapital 2023-06-01 2024-08-31 10784771 countries:EnglandWales 2023-06-01 2024-08-31 10784771 2023-05-31 10784771 core:RetainedEarningsAccumulatedLosses 2023-05-31 10784771 core:ShareCapital 2023-05-31 10784771 2022-06-01 2023-05-31 10784771 2023-05-31 10784771 core:CurrentFinancialInstruments core:WithinOneYear 2023-05-31 10784771 core:RetainedEarningsAccumulatedLosses 2022-06-01 2023-05-31 10784771 core:ShareCapital 2022-06-01 2023-05-31 10784771 2022-05-31 10784771 core:RetainedEarningsAccumulatedLosses 2022-05-31 10784771 core:ShareCapital 2022-05-31 iso4217:GBP xbrli:pure

Registration number: 10784771

Final Accounts
WLM Medical Solutions Ltd

Annual Report and Unaudited Abridged Financial Statements

for the Period from 1 June 2023 to 31 August 2024

 

WLM Medical Solutions Ltd

Contents

Company Information

1

Director's Report

2

Abridged Statement of Financial Position

3

Statement of Changes in Equity

4

Notes to the Unaudited Abridged Financial Statements

5 to 6

 

WLM Medical Solutions Ltd

Company Information

Director

Francesca Castiglioni

Registered office

12 Bridewell Place
Third Floor East
London
EC4V 6AP

 

WLM Medical Solutions Ltd

Director's Report for the Period from 1 June 2023 to 31 August 2024

The director presents her report and the abridged financial statements for the period from 1 June 2023 to 31 August 2024.

Director of the company

The director who held office during the period was as follows:

Francesca Castiglioni

Principal activity

The principal activity of the company is that of pharmaceutical industry connected to an Italian company

These are final trading accounts and the company will soon be dissolved.

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the director on 4 October 2024
 

.........................................
Francesca Castiglioni
Director

 

WLM Medical Solutions Ltd

(Registration number: 10784771)
Abridged Statement of Financial Position as at 31 August 2024

Note

2024
£

2023
£

Current assets

 

Cash at bank and in hand

 

8,586

3,732

Creditors: Amounts falling due within one year

(13,338)

(10,248)

Total assets less current liabilities

 

(4,752)

(6,516)

Accruals and deferred income

 

(3,337)

(3,333)

Net liabilities

 

(8,089)

(9,849)

Capital and reserves

 

Called up share capital

100

100

Retained earnings

(8,189)

(9,949)

Shareholders' deficit

 

(8,089)

(9,849)

For the financial period ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Income Statement and an Abridged Statement of Financial Position in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 4 October 2024
 

.........................................
Francesca Castiglioni
Director

 

WLM Medical Solutions Ltd

Statement of Changes in Equity for the Period from 1 June 2023 to 31 August 2024

Share capital
£

Retained earnings
£

Total
£

At 1 June 2023

100

(9,949)

(9,849)

Profit for the period

-

1,760

1,760

At 31 August 2024

100

(8,189)

(8,089)

Share capital
£

Retained earnings
£

Total
£

At 1 June 2022

100

9,409

9,509

Loss for the period

-

(19,358)

(19,358)

At 31 May 2023

100

(9,949)

(9,849)

 

WLM Medical Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 June 2023 to 31 August 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
12 Bridewell Place
Third Floor East
London
EC4V 6AP

These financial statements were authorised for issue by the director on 4 October 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

WLM Medical Solutions Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 1 June 2023 to 31 August 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 0 (2023 - 0).